Clinical Trial Update: DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for a Phase 1/2 study of DZD6008 in combination therapy for locally advanced or metastatic EGFR-mutant non-small cell lung cancer (TIAN-SH…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DZD6008

Snippet

Sponsor: Dizal Pharmaceuticals | Conditions: Non Small Cell Lung Cancer | Phase 1, Phase 2 | Status: RECRUITING